192 related articles for article (PubMed ID: 27406023)
21. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
[TBL] [Abstract][Full Text] [Related]
22. 11α-Hydroxyprogesterone, a potent 11β-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5α-reductase and cytochrome P450 17α-hydroxylase/17,20-lyase to produce C11α-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro.
Gent R; du Toit T; Swart AC
J Steroid Biochem Mol Biol; 2019 Jul; 191():105369. PubMed ID: 31039398
[TBL] [Abstract][Full Text] [Related]
23. Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5.
Estrada DF; Skinner AL; Laurence JS; Scott EE
J Biol Chem; 2014 May; 289(20):14310-20. PubMed ID: 24671419
[TBL] [Abstract][Full Text] [Related]
24. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
25. 17(E)-picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies.
Ajduković JJ; Djurendić EA; Petri ET; Klisurić OR; Celić AS; Sakač MN; Jakimov DS; Gaši KM
Bioorg Med Chem; 2013 Dec; 21(23):7257-66. PubMed ID: 24148837
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
28. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
[TBL] [Abstract][Full Text] [Related]
29. Steroid 17α-hydroxylase/17, 20-lyase (cytochrome P450 17A1).
Guengerich FP; McCarty KD; Tateishi Y; Liu L
Methods Enzymol; 2023; 689():39-63. PubMed ID: 37802581
[TBL] [Abstract][Full Text] [Related]
30. CYP17A1: a biochemistry, chemistry, and clinical review.
Porubek D
Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
[TBL] [Abstract][Full Text] [Related]
31. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Cheong EJY; Nair PC; Neo RWY; Tu HT; Lin F; Chiong E; Esuvaranathan K; Fan H; Szmulewitz RZ; Peer CJ; Figg WD; Chai CLL; Miners JO; Chan ECY
J Pharmacol Exp Ther; 2020 Sep; 374(3):438-451. PubMed ID: 32554434
[TBL] [Abstract][Full Text] [Related]
32. CYP17A1 exhibits 17αhydroxylase/17,20-lyase activity towards 11β-hydroxyprogesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway.
van Rooyen D; Yadav R; Scott EE; Swart AC
J Steroid Biochem Mol Biol; 2020 May; 199():105614. PubMed ID: 32007561
[TBL] [Abstract][Full Text] [Related]
33. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
34. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
[TBL] [Abstract][Full Text] [Related]
35. Kinetic processivity of the two-step oxidations of progesterone and pregnenolone to androgens by human cytochrome P450 17A1.
Gonzalez E; Guengerich FP
J Biol Chem; 2017 Aug; 292(32):13168-13185. PubMed ID: 28684414
[TBL] [Abstract][Full Text] [Related]
36. Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR.
Estrada DF; Laurence JS; Scott EE
J Biol Chem; 2013 Jun; 288(23):17008-17018. PubMed ID: 23620596
[TBL] [Abstract][Full Text] [Related]
37. Modified bile acids and androstanes-Novel promising inhibitors of human cytochrome P450 17A1.
Dzichenka Y; Shapira M; Yantsevich A; Cherkesova T; Grbović L; Savić M; Usanov S; Jovanović-Šanta S
J Steroid Biochem Mol Biol; 2021 Jan; 205():105777. PubMed ID: 33157220
[TBL] [Abstract][Full Text] [Related]
38. Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.
Vaillancourt J; Turcotte V; Caron P; Villeneuve L; Lacombe L; Pouliot F; Lévesque É; Guillemette C
Drug Metab Dispos; 2020 Feb; 48(2):75-84. PubMed ID: 31727674
[TBL] [Abstract][Full Text] [Related]
39. Role of cytochrome b5 in the modulation of the enzymatic activities of cytochrome P450 17α-hydroxylase/17,20-lyase (P450 17A1).
Bhatt MR; Khatri Y; Rodgers RJ; Martin LL
J Steroid Biochem Mol Biol; 2017 Jun; 170():2-18. PubMed ID: 26976652
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
